EP1109565A4 - Recepteur de gabab1aa - Google Patents

Recepteur de gabab1aa

Info

Publication number
EP1109565A4
EP1109565A4 EP99943923A EP99943923A EP1109565A4 EP 1109565 A4 EP1109565 A4 EP 1109565A4 EP 99943923 A EP99943923 A EP 99943923A EP 99943923 A EP99943923 A EP 99943923A EP 1109565 A4 EP1109565 A4 EP 1109565A4
Authority
EP
European Patent Office
Prior art keywords
gabab1aa
receptor
gabab1aa receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99943923A
Other languages
German (de)
English (en)
Other versions
EP1109565A1 (fr
Inventor
Nabil A Elshourbagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1109565A1 publication Critical patent/EP1109565A1/fr
Publication of EP1109565A4 publication Critical patent/EP1109565A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
EP99943923A 1998-09-01 1999-08-30 Recepteur de gabab1aa Withdrawn EP1109565A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14477998A 1998-09-01 1998-09-01
US144779 1998-09-01
PCT/US1999/019435 WO2000012106A1 (fr) 1998-09-01 1999-08-30 Recepteur de gabab1aa

Publications (2)

Publication Number Publication Date
EP1109565A1 EP1109565A1 (fr) 2001-06-27
EP1109565A4 true EP1109565A4 (fr) 2004-05-19

Family

ID=22510095

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99943923A Withdrawn EP1109565A4 (fr) 1998-09-01 1999-08-30 Recepteur de gabab1aa

Country Status (3)

Country Link
EP (1) EP1109565A4 (fr)
JP (1) JP2002523070A (fr)
WO (1) WO2000012106A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP438598A0 (en) 1998-06-29 1998-07-23 Garvan Institute Of Medical Research NPY-Y7 receptor gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046675A1 (fr) * 1996-05-30 1997-12-11 Novartis Ag Recepteurs metabotropes de gaba[b], ligands specifiques de ceux-ci et utilisations associees
WO1999051636A2 (fr) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Recepteur gaba b
WO1999061606A1 (fr) * 1998-05-29 1999-12-02 The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services RECEPTEURS MAMMALIENS gb2 ET GABA¿B?

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046675A1 (fr) * 1996-05-30 1997-12-11 Novartis Ag Recepteurs metabotropes de gaba[b], ligands specifiques de ceux-ci et utilisations associees
WO1999051636A2 (fr) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Recepteur gaba b
WO1999061606A1 (fr) * 1998-05-29 1999-12-02 The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services RECEPTEURS MAMMALIENS gb2 ET GABA¿B?

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOWERY N G: "Metabotropic GABAB receptors cloned at last", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 4, 1 April 1997 (1997-04-01), pages 103, XP004058669, ISSN: 0165-6147 *
DATABASE EMBL [online] 16 November 1998 (1998-11-16), "Homo sapiens mRNA for GABA-B R1a receptor", XP002274178, retrieved from EBI Database accession no. AJ225028 *
DATABASE EMBL [online] 16 October 2001 (2001-10-16), "Gamma-aminobutyric acid type B receptor, subunit 1 precursor (GABA-B receptor 1) (GABA-B-R1) (Gb1)", XP002274179, retrieved from EBI Database accession no. Q9WV18 *
DATABASE EMBL [online] 4 September 1997 (1997-09-04), "Homo sapiens mRNA for GABA-BR1a (hGB1a) receptor", XP002274177, retrieved from EBI Database accession no. Y11044 *
GRIFA A. ET AL: "GABA (Gamma-Amino-Butyrc Acid) Neurotransmission: Identification and Fine Mapping of the Human GABA-B Receptor Gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 250, 18 September 1998 (1998-09-18), pages 240 - 245 *
KAUPMANN K. ET AL.: "Human Gamma-aminobutyric acid type B receptors are differentially expressed and regulate inwadly rectifying K+ channels", PROC. NATL. ACAD. SCI. USA, vol. 95, December 1998 (1998-12-01), pages 14991 - 14996, XP000867019 *
KERR D I B ET AL: "GABABETA RECEPTORS", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 67, no. 2, 1995, pages 187 - 246, XP002916277, ISSN: 0163-7258 *
See also references of WO0012106A1 *

Also Published As

Publication number Publication date
EP1109565A1 (fr) 2001-06-27
JP2002523070A (ja) 2002-07-30
WO2000012106A1 (fr) 2000-03-09

Similar Documents

Publication Publication Date Title
DE59912932D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE59912303D1 (en) Arylphenylsubstituierte cyclische ketoenole
PL345247A1 (en) Retinoid-associated receptor regulators
DE59903023D1 (en) Perorale wirkstoff-suspension
DE59914151D1 (en) Arylalkanoylpyridazine
GB9826359D0 (en) Novel receptors
DE60042897D1 (en) Photovervielfacherröhre
IL146151A0 (en) Human-g-protein receptor
DE59904407D1 (en) Chromanderivate
EP1084142A4 (fr) Recepteur de gpr35a
DE69821502D1 (en) Boroskop
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) 取代的3-硫代氨基甲酰基吡唑類化合物
EP0973800A4 (fr) Nouveau recepteur
DE59900495D1 (en) Multimetalloxidmassen
PL347397A1 (en) Substituted 3-aryl-pyrazoles
DE59900471D1 (en) Inchbremseinrichtung
GB9819420D0 (en) Novel receptor
EP1079848A4 (fr) Recepteur d'angiostatine
PL345866A1 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (zh) 取代的苯甲酰基環已二酮類化合物
EP1083909A4 (fr) RECEPTEUR DE hCEPR
EP1131335A4 (fr) Hlwar77 du recepteur de 7tm
GB9827016D0 (en) Receptor protein
DE59905941D1 (en) Methoximinophenylessigsäureamide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/68 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 07K 16/28 B

Ipc: 7C 07K 14/705 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040624